// App-Quantinova.ai

e16542 : Real-world study of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA+P): Patient characteristics and treatment persistence.

Researchers

Presenter

  • Kelvin A. Moses

Principal Investigators

  • David F. Penson

  • Neil M. Schultz

  • Fei Shi

  • Samuel Wilson

  • Bruce A. Brown

  • Arie Barlev

  • Scott Flanders

Medical Centers

  • Vanderbilt University School of Medicine, Nashville, TN

  • Astellas Pharma, Inc., Northbrook, IL

  • Medication, Inc., San Francisco, CA

Locations

  • United States

Companies

  • Astellas Pharma Inc.

  • Medivation, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Enzalutamide

  • Prednisone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved